|
1
|
D'Haens G, Vermeire S, Lambrecht G, Baert
F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander
Woude J, et al: Increasing infliximab dose based on symptoms,
biomarkers, and serum drug concentrations does not increase
clinical, endoscopic, and corticosteroid-free remission in patients
with active luminal Crohn's disease. Gastroenterology.
154:1343–1351e1. 2018. View Article : Google Scholar
|
|
2
|
Tan B, Li P, Lv H, Yang H, Li Y, Li J,
Wang O and Qian JM: Treatment of vitamin D deficiency in Chinese
inflammatory bowel disease patients: A prospective, randomized,
open-label, pilot study. J Dig Dis. 19:215–224. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ling XH, Yu X, Kong DJ, Hu CY, Hong Y and
Yang XM: Treatment of inflammatory bowel disease with Chinese drugs
administered by both oral intake and retention enema. Chin J Integr
Med. 16:222–228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Buckley JP, Kappelman MD, Allen JK, Van
Meter SA and Cook SF: The burden of comedication among patients
with inflammatory bowel disease. Inflamm Bowel Dis. 19:2725–2736.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun CM, Wu J, Zhang H, Shi G and Chen ZT:
Circulating miR-125a but not miR-125b is decreased in active
disease status and negatively correlates with disease severity as
well as inflammatory cyto-kines in patients with Crohn's disease.
World J Gastroenterol. 23:7888–7898. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maerten P, Shen C, Colpaert S, Liu Z,
Bullens DA, van Assche G, Penninckx F, Geboes K, Vanham G,
Rutgeerts P, et al: Involvement of interleukin 18 in Crohn's
disease: Evidence from in vitro analysis of human gut inflammatory
cells and from experimental colitis models. Clin Exp Immunol.
135:310–317. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reuter BK and Pizarro TT: Commentary: The
role of the IL-18 system and other members of the IL-1R/TLR
superfamily in innate mucosal immunity and the pathogenesis of
inflammatory bowel disease: Friend or foe. Eur J Immunol.
34:2347–2355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fang L, Pang Z, Shu W, Wu W, Sun M, Cong Y
and Liu Z: Anti-TNF Therapy induces CD4+ T-cell
production of IL-22 and promotes epithelial repairs in patients
with Crohn's disease. Inflamm Bowel Dis. 24:1733–1744. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang GX, Sun Y, Tsuneyama K, Zhang W,
Leung PS, He XS, Ansari AA, Bowlus C, Ridgway WM and Gershwin ME:
Endogenous interleukin-22 protects against inflammatory bowel
disease but not autoimmune cholangitis in dominant negative form of
transforming growth factor beta receptor type II mice. Clin Exp
Immunol. 185:154–164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li LJ, Gong C, Zhao MH and Feng BS: Role
of interleukin-22 in inflammatory bowel disease. World J
Gastroentero. 20:18177–18188. 2014. View Article : Google Scholar
|
|
11
|
Mizoguchi A: Healing of intestinal
inflammation by IL-22. Inflamm Bowel Dis. 18:1777–1784. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arj A, Razavizadeh M, Mohammadi H,
Nikoueinejad H and Akbari H: The correlation between the numerical
status of Th22 cells and serum level of IL-22 with severity of
ulcerative colitis. Iran J Allergy Asthma Immuno. 17:78–84.
2018.
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔC T method. Methods. 25:402–408.
2001. View Article : Google Scholar
|
|
14
|
Nikiteas N, Yannopoulos A,
Chatzitheofylaktou A and Tsigris C: Heterozygosity for
interleukin-18-607 A/C polymorphism is associated with risk for
colorectal cancer. Anticancer Res. 27:3849–3853. 2007.
|
|
15
|
Haghshenas MR, Hosseini SV, Mahmoudi M,
Saberi-Firozi M, Farjadian S and Ghaderi A: IL-18 serum level and
IL-18 promoter gene polymorphism in Iranian patients with
gastrointestinal cancers. J Gastroenterol Hepatol. 24:1119–1122.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo JY, Qin AQ, Li RK, Yang CM, Huang FD,
Huang ZY and Guo HJ: Association of the IL-18 gene polymorphism
with susceptibility to colorectal cancer. Zhonghua Wei Chang Wai Ke
Za Zhi. 15:400–403. 2012.In Chinese. PubMed/NCBI
|
|
17
|
Ben Aleya W, Sfar I, Habibi I, Mouelhi L,
Aouadi H, Makhlouf M, Ayed-Jendoubi S, Najjar T, Ben Abdallah T,
Ayed K, et al: Interleukin-18 gene polymorphisms in tunisian
patients with inflammatory bowel disease. Digestion. 83:269–274.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takagawa T, Tamura K, Takeda N, Tomita T,
Ohda Y, Fukunaga K, Hida N, Ohnishi K, Hori K, Kosaka T, et al:
Association between IL-18 gene promoter polymorphisms and
inflammatory bowel disease in a Japanese population. Inflamm Bowel
Dis. 11:1038–1043. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aizawa Y, Sutoh S, Matsuoka M, Negishi M,
Torii A, Miyakawa Y, Sugisaka H, Nakamura M and Toda G: Association
of interleukin-18 gene single-nucleotide polymorphisms with
susceptibility to inflammatory bowel disease. Tissue Antigens.
65:88–92. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Haas SL, Andreas Koch W, Schreiber S,
Reinhard I, Koyama N, Singer MV and Böcker U: -137 (G/C) IL-18
promoter polymorphism in patients with inflammatory bowel disease.
Scand J Gastroentero. 40:1438–1443. 2005. View Article : Google Scholar
|
|
21
|
Dong YB and Chen GY: Association analysis
of IL-18 gene polymorphisms and ulcerative colitis in Chinese Han
population. Chin J Clin Gastroenterol. 21:21–22. 2009.In
Chinese.
|
|
22
|
Bank S, Andersen PS, Burisch J, Pedersen
N, Roug S, Galsgaard J, Ydegaard Turino S, Brodersen JB, Rashid S,
Kaiser Rasmussen B, et al: Polymorphisms in the toll-like receptor
and the IL-23/IL-17 pathways were associated with susceptibility to
inflammatory bowel disease in a danish cohort. PLoS One.
10:e01453022015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dong YB, Bo WL, Feng XB and Chen GY:
Association between single nucleotide polymorphismin of
interleukin-18 gene and ulcerative colitis in Han population of
Shanghai. World Chin J Digestology. 16:2785–2787. 2008.In Chinese.
View Article : Google Scholar
|
|
24
|
Motamed F, Famouri F, Najafi M, Moazzami
K, Farahmand F, Khodadad A, Fallahi GH, Khatami GR and Rezaei N:
Response to induction therapy in a pediatric population of
inflammatory bowel disease. Z Gastroenterol. 48:748–752. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wiercinska-Drapalo A, Flisiak R,
Jaroszewicz J and Prokopowicz D: Plasma interleukin-18 reflects
severity of ulcerative colitis. World J Gastroenterol. 11:605–608.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Striz I: Cytokines of the IL-1 family:
Recognized targets in chronic inflammation underrated in organ
transplantations. Clin Sci. 131:2241–2256. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tillack C, Ehmann LM, Friedrich M,
Laubender RP, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek
A, Wetzke M, et al: Anti-TNF antibody-induced psoriasiform skin
lesions in patients with inflammatory bowel disease are
characterised by interferon-gamma-expressing Th1 cells and
IL-17A/IL-22- expressing Th17 cells and respond to anti-IL-12/IL-23
antibody treatment. Gut. 63:567–577. 2014. View Article : Google Scholar
|
|
28
|
Yu LZ, Wang HY, Yang SP, Yuan ZP, Xu FY,
Sun C and Shi RH: Expression of interleukin-22/STAT3 signaling
pathway in ulcerative colitis and related carcinogenesis. World J
Gastroenterol. 19:2638–2649. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ratsimandresy RA, Indramohan M,
Dorfleutner A and Stehlik C: The AIM2 inflammasome is a central
regulator of intestinal homeostasis through the IL-18/IL-22/STAT3
pathway. Cell Mol Immunol. 14:127–142. 2017. View Article : Google Scholar :
|
|
30
|
Turner JE, Stockinger B and Helmby H:
IL-22 mediates goblet cell hyperplasia and worm expulsion in
intestinal helminth infection. PLoS Pathog. 9:e10036982013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sugimoto K, Ogawa A, Mizoguchi E,
Shimomura Y, Andoh A, Bhan AK, Blumberg RS, Xavier RJ and Mizoguchi
A: IL-22 ameliorates intestinal inflammation in a mouse model of
ulcerative colitis. J Clin Invest. 118:534–544. 2008.PubMed/NCBI
|
